We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Deficiencia de butirilcolinesterasa: Una revisión narrativa de la literatura.
- Authors
Vega Useche, Leonel Santiago; Gualdrón Frías, Carlos Andrés; Calderón Nossa, Laura Tatiana; Larrotta Salamanca, Lady Ximena; Rueda Marín, Elkin Duván
- Abstract
Butyrylcholinesterase is an enzyme that metabolizes depolarizing neuromuscular relaxants, such as succinylcholine, a chosen medication for procedures that require short-term muscular paralysis, to facilitate endotracheal intubation in patients undergoing emergency procedures, for example. Butyrylcholinesterase deficiency can be defined as a quantitative reduction of the enzyme and its activity to hydrolyze molecules, becoming the main cause of prolonged neuromuscular blockade after the administration of neuromuscular relaxants such as succinylcholine. It is a pathological condition that can be of either hereditary or acquired origin; being more common the enzymatic deficiency of genetic origin and of autosomal recessive character, occurring in approximately one in 3,200 to 5,000 people worldwide. Its clinical manifestation is characterized by persistent muscle relaxation which can lead to acute respiratory failure. The diagnosis must be oriented to the identification of its clinical characteristics, serological quantification, and neuromuscular monitoring. Because a cure does not exist for this deficiency, management should be directed to mechanical ventilation of the patient, until the used drug is fully metabolized. This article aims to review the state of the art, describing its epidemiology, etiology, pathophysiology, clinical manifestations, and updates in its diagnosis and treatment.
- Subjects
ADULT respiratory distress syndrome; BUTYRYLCHOLINESTERASE; NEUROMUSCULAR blockade; SYMPTOMS; TRACHEA intubation
- Publication
Salud Uninorte, 2021, Vol 37, Issue 3, p738
- ISSN
0120-5552
- Publication type
Article
- DOI
10.14482/sun.37.3.616.831